The Annals
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 18 July 2006, www.theannals.com, DOI 10.1345/aph.1G723.
 The Annals of Pharmacotherapy: Vol. 40, No. 7, pp. 1344-1352. DOI 10.1345/aph.1G723
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmiedeskamp, M. R
Right arrow Articles by Kockler, D. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmiedeskamp, M. R
Right arrow Articles by Kockler, D. R

NEW DRUG DEVELOPMENTS

Human Papillomavirus Vaccines

Mia R Schmiedeskamp, PharmD PhD

Pharmacy Practice Resident, Virginia Commonwealth University Health System, Richmond, VA

Denise R Kockler, PharmD BCPS

Director, Drug Information Services, Virginia Commonwealth University Health System

Reprints: Dr. Schmiedeskamp, Virginia Commonwealth University Health System, PO Box 980042, Richmond, VA 23298-0042, fax 804/225-3920, mschmiedeskamp{at}mcvh-vcu.edu

OBJECTIVE: To review the pharmacology, efficacy, safety, tolerability, and pharmacoeconomics of Cervarix and Gardasil, 2 human papillomavirus (HPV) vaccines.

DATA SOURCES: English-language articles were obtained by MEDLINE search (1966-February 2006) using the key words human papillomavirus vaccine, Cervarix, and Gardasil. Bibliographies of selected articles were used to identify additional sources.

STUDY SELECTION AND DATA EXTRACTION: All available published articles or abstracts reporting the results of human studies of HPV vaccines were reviewed for inclusion in this article. Additional information about ongoing clinical trials was obtained from manufacturers' Web sites.

DATA SYNTHESIS: Cervarix and Gardasil are recombinant vaccines against HPV. Cervarix targets HPV-16 and -18, which are responsible for 70% of cervical cancers. Gardasil also targets HPV-16 and -18, plus the HPV-6 and -11 types responsible for more than 80% of genital warts. Both vaccines have been effective in preventing persistent infection with targeted HPV types and in preventing cervical intraepithelial lesions, while Gardasil has also been effective in preventing vulvar and vaginal neoplasia and genital warts. Both vaccines have been well tolerated, with the most common adverse effects occurring at the injection site. Phase III trials are ongoing to further evaluate vaccine efficacy.

CONCLUSIONS: Cervarix and Gardasil are effective for prevention of HPV infection and cervical lesions. Issues remaining to be addressed include duration of protection, efficacy for prevention of cervical cancer, optimal age for vaccination, feasibility of application to the developing world, the ideal combination of HPV subtypes, and the most efficient combination of vaccination and cervical cancer screening.

Key Words: Cervarix, Gardasil, human papillomavirus vaccine

Published Online, July 18, 2006. www.theannals.com, DOI 10.1345/aph.1G723

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-06-019-H01




homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.